Erythroleukemia-like syndrome due to busulfan toxicity in polycythemia vera.
Over a 19-year period, a patient with polycythemia vera who had undergone a splenectomy received six courses of busulfan for recurrent thrombocytosis. The total dose of busulfan given for the sixth course was greater than that used for the previous ones. Severe pancytopenia followed, which persisted for 4 months. During this period there was marked erythroid hyperplasia in the bone marrow with striking dyserythropoiesis; PAS-positive red cell precursors, as well as moderate numbers of circulating normoblasts and evidence of chronic and acute hemolysis, were present. All of these findings reverted to normal without therapy, and the polycythemic state eventually recurred. These events are interpreted as an unusual marrow reaction following busulfan overdosage rather than a transient erythroleukemia.
D000328:Adult; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001855:Bone Marrow Diseases / Q000139:chemically induced*; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced* / Q000150:complications; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013577:Syndrome; D013922:Thrombocytosis / Q000188:drug therapy
D002066:Busulfan